

UNC HIGH THROUGHPUT SEQUENCING FACILITY

PRESENTS

a Genomic Symposium

“Embracing Unique Next-Gen Sequencing Technologies for Unique Sample Types”

Join us for this free seminar exploring HTG Technology

Where: Bondurant Hall, Room G074

When: Thursday April 13, 2017

Time: 12:30 - 4:30 pm

For Visitor Parking please

see: <https://maps.unc.edu/parking/dogwood-deck/>

[//maps.unc.edu/parking/dogwood-deck/](https://maps.unc.edu/parking/dogwood-deck/)

Lunch provided by Dept. of Genetics

RSVP to: Katherine Berger: kberger@email.unc.edu by April 11th

Symposium Agenda:

<u>Start</u>	<u>Finish</u>	<u>Subject</u>	<u>Speaker</u>
12:30pm	1:00pm	Lunch – Opening Remarks	Caitlin Brown
1:00pm	1:45pm	Intro to HTG Molecular Technology	BJ Kerns
1:45pm	2:30pm	miRNA in Exosomes from Plasma	Mehmet Kesimer, Ph.D.
2:30pm	2:45pm	Break	
2:45pm	3:30pm	miRNA Prognostic Signature Development	Mary-Beth Joshi, B.S., MPH
3:30pm	4:15pm	IO Urothelial Ca: Nivolumab response study	Amy Wehn, Ph.D.
4:15pm	4:30pm	Closing Remarks	Caitlin Brown

Meet The Speakers:

Caitlin Brown, Genomic Account Manager – HTG Molecular

BJ Kerns, VP Global Scientific/Technical Affairs – HTG Molecular

Mehmet Kesimer, Ph.D., is an Associate Professor of Pathology and Laboratory Medicine, and an investigator of the Cystic Fibrosis and Pulmonary Research Center. He leads Project II for the UNC Center for Tobacco Regulatory Science and Lung Health.

Mary-Beth Joshi, B.S., MPH is the Assistant Director, Biobank & Translational Research Core; Assistant Director, Research Support Services - Duke University Medical Center. She along with Dr. David Harpole, MD is a part of the SPECS lung consortium P1.05-001 creation in early validation of prognostic and miRNA signatures for squamous cell lung carcinoma.

Amy Wehn, PhD is a Senior Manager, Immuno-Oncology Biomarker Development Programs – HTG Molecular.